Curiously, some bariatric RYGB patients experience up to a 10-fold increase in post-meal active GLP-1 plasmatic levels (from fasting 5 pM to post-prandial 3065 pM) (146), and have a 2- to 3-fold higher glucose-stimulated Insulin secretion (147), which in some diabetic patients results in GLP-1-mediated hyperinsulinemic hypoglycaemia that requires GLP-1 antagonism or surgical reversal of the intestinal anatomy (148)
doi:10.1016/j.eururo.2013.10.040
Participants in the semaglutide group achieved a weight loss of at least 5%, 10%, or 15%, and improvements in secondary endpoints, such as waist circumference, blood pressure, and lipid levels, compared to the placebo group
are met." However, Novo Nordisk owns multiple patents protecting its medications that use semaglutide, including the diabetes drug Ozempic, and said that organizations selling semaglutide products "may be infringing Novo Nordisk's intellectual property rights and/or violating applicable law." The company added that it "will take such actions as it deems necessary and appropriate to protect its intellectual property rights." "Nobody knows how [compounding pharmacies are] getting it," said Karl Nadolsky, an endocrinologist at Spectrum Health